The FDA has approved Epioxa™ HD 0.239% and Epioxa™ 0.177% for use in epithelium-on corneal collagen CXL for the treatment of ...

In 2 phase 3 studies, acoltremon 0.003% met primary endpoints, demonstrating statistically significant tear production at day 14.

Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries.

Researchers assessed the quality of life measures of patients with thyroid eye disease treated with Veligrotug, a full antagonist humanized mAb to IGF-1R.

Researchers compared the use of aflibercept 8 mg and 2 mg in patients with various retinal vein occlusion subtypes.

The study published in JAMA Ophthalmology – the first epidemiologic study to home in on eye injuries in pickleball – reviewed ...

Explainable artificial intelligence (XAI) can identify clinically significant diabetic retinal neurodegeneration (DRN) on ...

Investigators conducted a large-scale retrospective cohort study of the prevalence and age of onset of retinal detachment and ...

HealthDay News — For cancer survivors, postdiagnosis smoking cessation is associated with improved overall survival, according to a study published in the October issue of the Journal of the National ...

A phase 2 study supports the use of a microRNA eye drop for patients with corneal damage or dry eye disease.

Investigators reviewed the long-term outcomes of patients who completed the PANORAMA clinical trial and have since sought standard clinical care.

The US Food and Drug Administration has approved the supplemental new drug application for Zoryve (roflumilast) cream 0.05 percent for the topical treatment of mild-to-moderate atopic dermatitis in ...